Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT06519526 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Peripheral T Cell Lymphoma

Interventions

DRUG: SHR-0302
DRUG: SHR-2554

Sponsor

Fudan University